Analysis of age-specific cytogenetic changes among 515 patients withacute myeloid leukemia.
10.3760/cma.j.issn.1003-9406.2019.06.005
- Author:
Lin LIU
1
;
Huan XU
;
Zhimei CHEN
;
Jiyu LOU
;
Huanping WANG
;
Jie JIN
Author Information
1. Department of Hematology, the First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, China. Email: jiej0503@163.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Chromosome Aberrations;
Cytogenetic Analysis;
Cytogenetics;
Humans;
Karyotype;
Karyotyping;
Leukemia, Myeloid, Acute;
Middle Aged;
Myelodysplastic Syndromes;
Prognosis
- From:
Chinese Journal of Medical Genetics
2019;36(6):552-555
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To characterize cytogenetic changes and prognosis of patients with acute myeloid leukemia (AML) from different age groups.
METHODS:The karyotypes of 515 AML patients were analyzed by using short-term culture of bone marrow cells and R-banding technique. Combined with FAB typing and genetic testing, cytogenetic changes and prognosis of different age groups were analyzed.
RESULTS:The abnormal cloning rate was 54.6% among the 515 patients. The abnormal cloning rate and adverse risk karyotype proportion of those with myeloproliferative syndromes (MDS) and secondary AML were higher than those with de novo AML (P = 0.027; P<0.01). A significant difference was found in the number of structural abnormalities and proportion of favorable risk karyotypes among different age groups (P = 0.026; P = 0.004). And there was also a significant difference in the abnormal cloning rate between different FAB types (P<0.01). In those with non-acute promyelocytic leukemia (APL), the expression level of WT1 gene seemed to affect the prognosis. The survival rate of patients with karyotypes of adverse risk was lower than those with karyotypes of favorable risk (P = 0.015). The survival rate of the ≥60-year-old group was lower than the ≤30-year-old and 31 to 59-year-old groups (P<0.01, P<0.01).
CONCLUSION:The karyotypes of AML patients have different age distribution characteristics. The survival rate of ≥60-years-old group and karyotype of poor prognosis is low. Patients with MDS with secondary AML have a poor prognosis.
